Gilead struck a deal with PepStar Therapeutics that includes $1.28 billion in upfront payments for a Phase 1 oral IL-23 program, signaling a push into inflammation therapeutics with small-molecule convenience. The agreement places the California biopharma in the competitive IL-23 landscape while targeting the market pull for oral dosing. Gilead also framed the expansion as part of ongoing portfolio development in inflammation. For PepStar, the upfront provides capital to advance the early asset, while for Gilead the move adds near- to mid-term optionality as it balances larger clinical and platform investments. With IL-23 still a major area of drug development activity, an upfront of this size reinforces that late-stage and differentiated formulations—including oral—remain a priority theme for strategic licensing.